Cover - USD ($) $ in Millions |
12 Months Ended | ||
---|---|---|---|
Dec. 31, 2021 |
Apr. 19, 2022 |
Jun. 30, 2021 |
|
Cover [Abstract] | |||
Entity Registrant Name | Zivo Bioscience, Inc. | ||
Entity Central Index Key | 0001101026 | ||
Document Type | 10-K/A | ||
Amendment Flag | true | ||
Entity Voluntary Filers | No | ||
Current Fiscal Year End Date | --12-31 | ||
Entity Well Known Seasoned Issuer | No | ||
Entity Small Business | true | ||
Entity Shell Company | false | ||
Entity Emerging Growth Company | false | ||
Entity Current Reporting Status | Yes | ||
Document Period End Date | Dec. 31, 2021 | ||
Entity Filer Category | Non-accelerated Filer | ||
Document Fiscal Period Focus | FY | ||
Document Fiscal Year Focus | 2021 | ||
Entity Common Stock Shares Outstanding | 9,419,660 | ||
Entity Public Float | $ 29.2 | ||
Auditor Name | BDO USA, LLP | ||
Auditor Location | Troy, Michigan | ||
Auditor Firm Id | 243 | ||
Document Annual Report | true | ||
Entity File Number | 001-40449 | ||
Entity Incorporation State Country Code | NV | ||
Entity Tax Identification Number | 87-0699977 | ||
Entity Interactive Data Current | Yes | ||
Icfr Auditor Attestation Flag | false | ||
Entity Address Address Line 1 | 21 East Long Lake Road | ||
Entity Address Address Line 2 | Suite 100 | ||
Entity Address City Or Town | Bloomfield Hills | ||
Entity Address State Or Province | MI | ||
Entity Address Postal Zip Code | 48304 | ||
City Area Code | 248 | ||
Local Phone Number | 452 9866 | ||
Security 12b Title | Common Stock, $0.001 par value per share | ||
Trading Symbol | ZIVO | ||
Security Exchange Name | NASDAQ | ||
Document Transition Report | false | ||
Amendment Description | Zivo Bioscience, Inc. (the “Company”) is filing this Amendment No. 1 (this “Amendment”) to its Annual Report on Form 10-K for the year ended December 31, 2021, as filed on April 22, 2022 (the “Original Form 10-K”) with the Securities and Exchange Commission (the “SEC”), solely to provide the Part III information of Form 10-K that was to be incorporated by reference from the Company’s definitive proxy statement for its 2022 Annual Meeting of Stockholders (the “Proxy Statement”) because the Proxy Statement will not be filed with the SEC within 120 days after the end of the Company’s fiscal year ended December 31, 2021. This Form 10-K/A hereby amends and restates in their entirety Items 10 through 14 of Part III of the Original Form 10-K. In addition, as required by Rule 12b-15 under the Securities Exchange Act of 1934, as amended, new certifications by our principal executive officer and principal financial officer are filed as Exhibits 31.1 and 31.2 to this Amendment under Item 15 of Part IV hereof. Because no financial statements have been included in this Amendment and this Amendment does not contain or amend any disclosure with respect to Items 307 and 308 of Regulation S-K, paragraphs 3, 4, and 5 of the certifications have been omitted. Except as described above, no other changes have been made to the Original Form 10-K, and this Amendment does not amend, update or change any other items or disclosures in the Original Form 10-K. The Original Form 10-K continues to speak as of its original filing date. This Amendment does not reflect subsequent events occurring after the filing date of the Original Form 10-K or modify or update in any way disclosures in the Original Form 10-K. |